23 days ago
LLY
AnalystsAndrew BaumAndrew Baum's Stock Forecasts
AnalystsAndrew Baum
Analyst Ranking
Top 17%
#754 out of 4563 analysts
Average Return
+16.53%
Win Rate
68%15 out of 22
Risk vs Reward
Poor
Good
Andrew Baum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +145.62% | $318.43 | $782.12 | 2023-03-02 - 2024-03-01 | Strong Buy |
Eli Lilly & CoLLY | +61.42% | $453.59 | $732.20 | 2023-07-25 - 2024-04-24 | Strong Buy |
Eli Lilly & CoLLY | +45.16% | $230.36 | $334.38 | 2021-09-28 - 2022-09-28 | Strong Buy |
Abbvie IncABBV | +37.74% | $108.22 | $149.06 | 2021-03-11 - 2022-03-11 | Strong Buy |
Abbvie IncABBV | +28.56% | $93.95 | $120.78 | 2020-09-01 - 2021-08-31 | Strong Buy |
Andrew Baum Analyst Color
Get additional color on Andrew Baum's coverage of popular stocks
6 months ago
LLY
6 months ago
PFE
9 months ago
LLY
a year ago
MRK
Andrew Baum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 5 | Strong Buy | $895.00 | +22.23% | Maintains | 23 days ago |
AlvotechALVO | 3 | Hold | $10.00 | -26.14% | Upgrades | 6 months ago |
Pfizer IncPFE | 4 | Hold | $35.00 | +33.23% | Maintains | 6 months ago |
Merck & Co IncMRK | 6 | Strong Buy | $130.00 | N/A | Upgrades | a year ago |
Bristol Myers Squibb CoBMY | 4 | Strong Buy | $90.00 | N/A | Maintains | 2 years ago |
Abbvie IncABBV | 4 | Strong Buy | $170.00 | N/A | Reiterates | 2 years ago |
Royalty Pharma PLCRPRX | 1 | Strong Buy | $50.00 | N/A | Upgrades | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.